AGER and myeloid sarcoma: Studies have shown that decreased levels of sRAGE in patients with autoimmune disorders, such as MS (42), systemic lupus erythematosus (43), and Guillain-Barré syndrome (44), correlate with increased inflammatory activity and clinical manifestations, suggesting that reduced sRAGE may lead to enhanced RAGE activation and contribute to disease progression (41).